Weight Loss Injections vs Diet and Exercise: Which Works?

Weight loss injections vs diet is not really an either-or choice. In the big trials, the medicines semaglutide (Wegovy) and tirzepatide (Mounjaro) led to far more weight loss on average than diet and exercise advice alone. But they were tested alongside diet and activity advice, not instead of it. They are only for people who meet medical criteria, some of the weight lost is lean mass (including muscle), and much of it tends to come back when they stop. Whether a medicine is right for you is a decision for you and your doctor. Training and nutrition matter whichever way you go.

This article is education only. It does not cover doses, and it never replaces advice from your doctor or prescriber. The legal and eligibility points are as of October 2026; they are a summary, not legal advice, and may be out of date.

Weight loss injections vs diet: the short answer

• The medicines win on the scale. In the big trials, people on them lost about 15 to 21% of their body weight on average over 68 to 72 weeks. In the semaglutide trial, people given diet and activity advice with a placebo lost about 2%.
• Support makes diet and exercise work better. In a two-year trial, people given ongoing support lost about 5 kg (11 lb) on average, against under 1 kg (2 lb) for people left to manage on their own.
• The best results come from combining them. The medicines were tested alongside diet and activity advice, and a trial that compared the two directly, using an older medicine of the same kind, found that medicine plus exercise did best, most clearly for body fat.
• The medicines have real costs: side effects, eligibility rules, some loss of lean mass (including muscle) along with fat, and weight regain when they stop.
• Diet and training are not optional extras. They help decide how much of the weight you lose is fat, and what happens afterwards.

What the injections are

The medicines people call "weight loss jabs" are prescription-only medicines in the UK and the US (as of October 2026) that copy gut hormones involved in appetite. They make you feel full sooner and hungry less often, so you eat less without having to fight your appetite as hard.

• Semaglutide is sold as Wegovy for weight management and as Ozempic for type 2 diabetes.
• Tirzepatide is sold as Mounjaro (for type 2 diabetes, and in the UK also for weight management) and, in the US, as Zepbound for weight management.

As of October 2026 they are licensed in the UK and FDA-approved in the US, and a doctor or another registered prescriber decides whether one is suitable for you.

What the trials show

These are averages from the large trials; individual results varied.

Trial	What people got	Average weight change
STEP 1 (Wilding and colleagues, New England Journal of Medicine, 2021)	Semaglutide plus diet and activity advice, 68 weeks	About −15%
STEP 1	Placebo plus the same advice	About −2%
SURMOUNT-1 (Jastreboff and colleagues, New England Journal of Medicine, 2022)	Tirzepatide at the highest dose tested, plus diet and activity advice, 72 weeks	About −21%

Diet and exercise programs are harder to compare, because they are tested in different ways on different people. Two examples:

• Support over two years. In a trial by Appel and colleagues (New England Journal of Medicine, 2011), 415 adults with obesity and at least one heart disease risk factor were given ongoing weight-loss support by phone, website and email, with or without in-person sessions, or were left to manage on their own. After two years, the supported groups had lost about 4.6 kg (10.1 lb) and 5.1 kg (11.2 lb) on average, and around 4 in 10 had lost at least 5% of their weight. The self-directed group lost about 0.8 kg (1.8 lb).
• A short, strict diet. In the trial by Lundgren and colleagues described below, adults with obesity lost an average of 13.1 kg (29 lb) on an eight-week low-calorie diet before any medicine or exercise began.

So a well-supported diet can produce real losses, but on average the medicines produced much larger ones than advice alone.

Why the comparison is not quite fair

When people say "the jab beat diet and exercise", they usually mean the drug group beat the placebo group in trials like STEP 1. But both groups were given the same general diet and activity advice. Nobody was given a structured strength training program or high protein targets.

So the trials show that the medicine adds a lot on top of basic advice, not that diet and exercise do not work.

The direct comparison: both together

One trial asked the question head-on. Lundgren and colleagues (New England Journal of Medicine, 2021) took adults with obesity who had first lost weight on an eight-week low-calorie diet, then split them into four groups for a year: exercise, liraglutide (an older medicine in the same family, also prescription-only in the UK and the US as of October 2026), both together, or placebo.

After a year, compared with the placebo group, the exercise group had kept off about 4.1 kg (9 lb) more, the medicine group about 6.8 kg (15 lb) more, and the group that did both about 9.5 kg (21 lb) more. The extra loss from the combination over the medicine alone was too small to be sure of, but body fat told a clearer story: compared with placebo, the combination group's body-fat percentage fell by about twice as much as with exercise or the medicine on its own.

In short, the medicine helps you eat less, and training helps decide how much of the weight you lose is fat.

Who the medicines are recommended for

Eligibility rules change, and whether any medicine is right for you is a decision for you and your doctor. As of October 2026:

• In England, NICE guidance (TA875) recommends semaglutide for adults with at least one weight-related health condition and a BMI of at least 35, or a BMI of 30 to 34.9 if they meet the criteria for a specialist weight management service. It is used within a specialist service, for up to two years.
• The semaglutide guidance uses lower BMI thresholds, usually 2.5 lower, for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background.
• NICE guidance (TA1026) also recommends tirzepatide for some adults living with obesity. NHS England is introducing it in phases, with a plan for who is prioritised first, across specialist weight services and GP practices.
• In the US, the FDA approved Zepbound in November 2023 for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. Wegovy is also approved there for weight management.

Weight-related conditions include things like high blood pressure, type 2 diabetes and high cholesterol. If you are pregnant, planning a pregnancy, or have a history of an eating disorder, raise it with your doctor before anything else.

The trade-offs

Side effects

Stomach and bowel side effects, such as nausea, diarrhoea, vomiting and constipation, are the most common. In SURMOUNT-4 (Aronne and colleagues, JAMA, 2024), for example, they were more frequent with tirzepatide than with placebo. Your prescriber will go through the less common but more serious risks with you.

Some of the weight is lean mass

In smaller groups within the trials that had body scans, roughly 39% of the weight lost on semaglutide (STEP 1) and roughly a quarter on tirzepatide (SURMOUNT-1) was lean mass. Lean mass is not all muscle, and any big weight loss takes some, but it is a reason to lift weights and eat enough protein. Ozempic, Wegovy and Mounjaro: how to keep your muscle covers what to do.

Weight tends to return when they stop

In the extension of STEP 1 (Wilding and colleagues, Diabetes, Obesity and Metabolism, 2022), people who stopped semaglutide had regained about two thirds of the weight they had lost one year later. Stopping Ozempic and weight gain looks at what the trials show and what helps.

Diet and exercise have trade-offs too

Losing weight without medicine means living with more hunger, and many people find a big loss hard to keep up on willpower alone. But there are no drug side effects, no eligibility rules, and the habits you build stay with you.

Not approved: "research" peptides and online pens

Products sold online as "research" semaglutide or tirzepatide, "not for human use", are not approved or licensed medicines in the UK or the US (as of October 2026), and that label does not make selling them lawful or using them safe. Buying pens without a prescription is not safe either. As of October 2026: in the UK these are prescription-only medicines, which may lawfully be sold or supplied only on a prescription from an appropriate practitioner, and selling or supplying them any other way, or possessing them with intent to supply, is an offence (maximum two years in prison). In the US, as of October 2026, the FDA says compounded versions are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are sold; it has received reports of dosing errors and side effects (990 reports for compounded semaglutide and more than 730 for compounded tirzepatide as of 31 May 2026), warns that "salt" forms such as semaglutide sodium and acetate are different active ingredients with no lawful basis for compounding, and has found counterfeit Ozempic. Its advice is to get a prescription from your doctor and fill it at a state-licensed pharmacy. You cannot know what is in an unlicensed product, and nobody has checked whether it is safe for you. This is a summary, not legal advice, and the law may have changed since it was checked.

Why training and nutrition matter either way

Whether or not you use a medicine, the same basics decide how good the result is:

• Lift weights two to four times a week, adding reps or weight over time, to keep as much muscle as you can.
• Put protein first. About 1.6 to 2.2 g per kg of body weight a day, towards the top while losing weight (base it on your goal weight if you have a lot to lose). On a medicine that reduces your appetite, eat the protein part of each meal first.
• Keep a daily step target. It supports fat loss and is easy to recover from.
• Lose at a sensible rate. About 0.5 to 1% of body weight a week helps protect muscle. If you are losing much faster and your strength is falling, tell your prescriber rather than changing anything yourself.
• Build habits that outlast the plan. Regular weigh-ins, a way of eating you enjoy and training you keep doing are what hold the result. How to lose fat without losing muscle explains each step.

The bottom line

Weight loss injections and diet and exercise are not an either-or choice, and whether a medicine is right for you is a decision for you and your doctor. Whichever way you go, the parts in your control are the same: lifting weights with progression, putting protein first, keeping a daily step target, losing at a sensible rate and building habits that outlast the plan. They help decide how much of the weight you lose is fat, and what happens afterwards. Ozempic, Wegovy and Mounjaro: how to keep your muscle covers the training and food side in more detail.